zuretinol
Phase 2- Indications
- Leber congenital amaurosis, Retinitis pigmentosa, Age-related macular degeneration
Company intelligence / Profile preview
Retinagenix
Seattle*?, Washington*?, USAprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company's lead program was zuretinol acetate, an oral synthetic retinoid for rare inherited retinal diseases such as LCA and RP caused by RPE65 or LRAT mutations. Zuretinol showed promise as a non-surgical alternative to gene therapy for these conditions. In January 2022, Eluminex Biosciences acquired the global rights to zuretinol from Retinagenix. The program's further development now resides with Eluminex[3][4][5].
Another related asset, BBP‑551, originated from the same scientific lineage and was advanced by BridgeBio subsidiary "Retinagenix Therapeutics," but this appears to be a separate entity or licensing arrangement[6].
As of early/mid‑2020s, there are no active clinical programs under the original "Retinagenix" entities; their main asset has been divested/discontinued.
Pipeline breadth before acquisition/discontinuation was one main clinical program.
No current commercial products.
- Therapeutic areas
- Ophthalmology
- Modalities
- Synthetic retinoids (e.g., zuretinol acetate)Small molecules (Vitamin A analogs/retinoids)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Asset sale partnership with Eluminex Biosciences for zuretinol acetate[3][4][5]
Beyond the preview
Go deeper on Retinagenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Retinagenix.